Matinas BioPharma (MTNB) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free MTNB Stock Alerts $0.17 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 2:27 PM | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16 at 7:09 AM | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16 at 7:00 AM | globenewswire.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024May 9, 2024 | globenewswire.comMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 7, 2024 | finance.yahoo.comMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingMay 2, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024April 30, 2024 | msn.comOral fungal infection treatment shows promise in preclinical trialsApril 30, 2024 | finance.yahoo.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 3, 2024 | msn.comMatinas Declines on Public OfferingApril 3, 2024 | globenewswire.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 1, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 28, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter.March 28, 2024 | finance.yahoo.comQ4 2023 Matinas BioPharma Holdings Inc Earnings CallMarch 27, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023March 27, 2024 | globenewswire.comMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 25, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | globenewswire.comMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 22, 2024 | finance.yahoo.comWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?March 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comMatinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsMarch 12, 2024 | marketbeat.comMatinas BioPharma (MTNB) to Release Quarterly Earnings on WednesdayMatinas BioPharma (NYSEAMERICAN:MTNB) will be releasing earnings on Wednesday, March 13, Yahoo Finance reports.March 3, 2024 | uk.finance.yahoo.comMatinas BioPharma Holdings, Inc. (MTNB)February 28, 2024 | wsj.comMatinas BioPharma Holdings Inc.February 26, 2024 | finance.yahoo.comMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionFebruary 23, 2024 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 20, 2024 | globenewswire.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 4, 2024 | seekingalpha.comAVBP ArriVent BioPharma, Inc.January 21, 2024 | morningstar.comMatinas BioPharma Holdings Inc MTNBJanuary 3, 2024 | finance.yahoo.comMatinas BioPharma to Present at Biotech Showcase 2024December 27, 2023 | finance.yahoo.comMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesDecember 21, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 21, 2023 | markets.businessinsider.comMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203December 21, 2023 | finance.yahoo.comMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 20, 2023 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and ForecastNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)November 10, 2023 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Matinas BioPharma Holdings Inc Earnings CallNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business ProgressNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 7, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelNovember 7, 2023 | finance.yahoo.comMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Investment of the Decade… (Ad)Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade. To get all the details of this controversial tech – click here now. MTNB Media Mentions By Week MTNB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.570.55▲Average Medical News Sentiment MTNB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼101▲MTNB Articles Average Week Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DRRX News JAN News CASI News PMN News APLM News MRKR News BCTX News IGC News FBIO News VYNE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MTNB) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
